SEARCH

SEARCH BY CITATION

References

  • 1
    Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007: 110: 17131722.
  • 2
    Hwang S T, Janik J E, Jaffe E S, Wilson W H. Mycosis fungoides and Sezary syndrome. Lancet 2008: 371: 945957.
  • 3
    Tessier-Marteau A, Le Corre Y, Gerard J et al. Peripheral blood Sezary cells and the diagnosis of Sezary syndrome. Ann Biol Clin (Paris) 2008: 66: 447453.
  • 4
    Miedema F, Willemze R, Terpstra F G, Van Vloten W A, Meijer C J, Melief C J. Regulatory activity of neoplastic T cells in Sezary syndrome on in vitro immunoglobulin production. Leuk Res 1984: 8: 873884.
  • 5
    Berger C L, Tigelaar R, Cohen J et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005: 105: 16401647.
  • 6
    Krejsgaard T, Gjerdrum L M, Ralfkiaer E et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome. Leukemia 2008: Dec; 22(12): 22302239.
  • 7
    Hartmann T B, Mattern E, Wiedemann N et al. Identification of selectively expressed genes and antigens in CTCL. Exp Dermatol 2008: 17: 324334.
  • 8
    Stadler R, Otte H G, Luger T et al. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998: 92: 35783581.
  • 9
    Thomsen K, Molin L, Volden G, Lange Wantzin G, Hellbe L. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1984: 64: 563566.
  • 10
    Thomsen K, Hammar H, Molin L, Volden G. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1989: 69: 536538.
  • 11
    Fitzpatrick J E, Mellette J R. Treatment of mycosis fungoides with isotretinoin. J Dermatol Surg Oncol 1986: 12: 626629.
  • 12
    Kessler J F, Jones S E, Levine N, Lynch P J, Booth A R, Meyskens F L Jr. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 1987: 123: 201204.
  • 13
    Miller V A, Benedetti F M, Rigas J R et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997: 15: 790795.
  • 14
    Prince H M, McCormack C, Ryan G et al. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Australas J Dermatol 2001: 42: 9197.
  • 15
    Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001: 19: 24562471.
  • 16
    Duvic M, Martin A G, Kim Y et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001: 137: 581593.
  • 17
    Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens V J. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002: 138: 325332.
  • 18
    Zhang C, Hazarika P, Ni X, Weidner D A, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002: 8: 12341240.
  • 19
    Budgin J B, Richardson S K, Newton S B et al. Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 2005: 141: 315321.
  • 20
    Bouwhuis S A, Davis M D, El-Azhary R A et al. Bexarotene treatment of late-stage mycosis fungoides and Sezary syndrome: development of extracutaneous lymphoma in 6 patients. J Am Acad Dermatol 2005: 52: 991996.
  • 21
    Benson M J, Pino-Lagos K, Rosemblatt M, Noelle R J. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007: 204: 17651774.
  • 22
    Coombes J L, Siddiqui K R, Arancibia-Carcamo C V et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007: 204: 17571764.
  • 23
    Kang S G, Lim H W, Andrisani O M, Broxmeyer H E, Kim C H. Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells. J Immunol 2007: 179: 37243733.
  • 24
    Mucida D, Park Y, Kim G, Turovskaya O et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007: 317: 256260.
  • 25
    Sun C M, Hall J A, Blank R B et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007: 204: 17751785.
  • 26
    Schambach F, Schupp M, Lazar M A, Reiner S L. Activation of retinoic acid receptor-alpha favours regulatory T cell induction at the expense of IL-17-secreting T helper cell differentiation. Eur J Immunol 2007: 37: 23962399.
  • 27
    Kim Y H, Willemze R, Pimpinelli N et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007: 110: 479484.
  • 28
    Vonderheid E C, Bernengo M G, Burg G et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002: 46: 95106.
  • 29
    Jarrousse V, Quereux G, Marques-Briand S, Knol A C, Khammari A, Dreno B. Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Eur J Dermatol 2006: 16: 636641.
  • 30
    Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001: 182: 1832.
  • 31
    Shevach E M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002: 2: 389400.
  • 32
    Shevach E M, McHugh R S, Piccirillo C A, Thornton A M. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001: 182: 5867.
  • 33
    Knol A C, Lemaitre F, Pandolfino M C et al. Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients. Exp Dermatol 2008: 17: 436445.
  • 34
    Viguier M, Lemaitre F, Verola O et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004: 173: 14441453.
  • 35
    Gjerdrum L M, Woetmann A, Odum N et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007: 21: 25122518.
  • 36
    Klemke C D, Fritzsching B, Franz B. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006: 20: 11231129.
  • 37
    Rensing-Ehl A, Gaus B, Bruckner-Tuderman L, Martin S F. Frequency, function and CLA expression of CD4+CD25+FOXP3+ regulatory T cells in bullous pemphigoid. Exp Dermatol 2007: 16: 1321.
  • 38
    Dejaco C, Duftner C, Schirmer M. Are regulatory T-cells linked with aging? Exp Gerontol 2006: 41: 339345.
  • 39
    Tiemessen M M, Mitchell T J, Hendry L, Whittaker S J, Taams L S, John S. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 2006: 126: 22172223.
  • 40
    Capriotti E, Vonderheid E C, Thoburn C J, Wasik M A, Bahler D W, Hess A D. Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leuk Lymphoma 2008: 49: 11901201.
  • 41
    Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995: 155: 11511164.
  • 42
    Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000: 101: 455458.
  • 43
    Berger C L, Hanlon D, Kanada D et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 2002: 99: 29292939.